Next Article in Journal
Organic–Inorganic Hybrid Pigments Based on Bentonite: Strategies to Stabilize the Quinoidal Base Form of Anthocyanin
Next Article in Special Issue
Biological Activity of Oleanolic Acid Derivatives HIMOXOL and Br-HIMOLID in Breast Cancer Cells Is Mediated by ER and EGFR
Previous Article in Journal
Ca2+-Dependent Effects of the Selenium-Sorafenib Nanocomplex on Glioblastoma Cells and Astrocytes of the Cerebral Cortex: Anticancer Agent and Cytoprotector
Previous Article in Special Issue
A Thiosemicarbazone Derivative as a Booster in Photodynamic Therapy—A Way to Improve the Therapeutic Effect
 
 
Review
Peer-Review Record

Cell Immunotherapy against Melanoma: Clinical Trials Review

Int. J. Mol. Sci. 2023, 24(3), 2413; https://doi.org/10.3390/ijms24032413
by Ivan Y. Filin, Yuri P. Mayasin, Chulpan B. Kharisova, Anna V. Gorodilova, Kristina V. Kitaeva, Daria S. Chulpanova, Valeriya V. Solovyeva and Albert A. Rizvanov *
Reviewer 1:
Reviewer 2:
Int. J. Mol. Sci. 2023, 24(3), 2413; https://doi.org/10.3390/ijms24032413
Submission received: 31 December 2022 / Revised: 22 January 2023 / Accepted: 23 January 2023 / Published: 26 January 2023
(This article belongs to the Special Issue Targeting Therapy for Cancer)

Round 1

Reviewer 1 Report

Cell immunotherapy against melanoma: clinical trials review

 

Authors Filin I. Y. et.al

 

The manuscript summarized the literature on ongoing clinical trials of cell-based therapy and adjuvant therapy on melanoma. Overall, the manuscript is well written. A couple of points need to be added before consideration for publication.

 

Line 58: please explain in more detail “genetic predisposition” or review the literature.

LN-44 [NCT02360579] also has been submitted to the FDA. Please include the review.

Line 519: What is the abbreviation of NAE?

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

Filin et al highlighted all the available adoptive cell-based immunotherapy for melanoma. Overall, the review is very well performed, which included all the current adoptive cell therapies against melanoma, but there are minor points the author would need to address.

 

Minor points:

1. It will be great if the author can include or discuss the possibility of using the stem-cell-like or progenitor T cells as one type of therapy for melanoma treatment.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop